Editing Botulinum toxin (section)

===Upper motor neuron syndrome===
Botulinum toxin type-A is now a common treatment for muscles affected by the [[upper motor neuron]] syndrome (UMNS), such as [[cerebral palsy]],<ref name=Farag2020/> for muscles with an impaired ability to effectively [[eccentric contraction|lengthen]]. Muscles affected by UMNS frequently are limited by [[weakness]], loss of [[reciprocal inhibition]], decreased movement control, and hypertonicity (including [[spasticity]]). In January 2014, Botulinum toxin was approved by UK's [[Medicines and Healthcare products Regulatory Agency]] (MHRA) for the treatment of ankle disability due to lower limb spasticity associated with stroke in adults.<ref name="DDD">{{cite web |url = http://www.dddmag.com/news/2014/02/uk-approves-new-botox-use?et_cid=3751256&et_rid=657808477&type=cta |title = UK Approves New Botox Use |archive-url = https://web.archive.org/web/20140222135115/http://www.dddmag.com/news/2014/02/uk-approves-new-botox-use?et_cid=3751256&et_rid=657808477&type=cta |archive-date=22 February 2014 |date = February 2014 |work = Drug Discovery and Development }}</ref> Joint motion may be restricted by severe muscle imbalance related to the syndrome, when some muscles are markedly hypertonic, and lack effective active lengthening. Injecting an overactive muscle to decrease its level of contraction can allow improved reciprocal motion, so improved ability to move and exercise.<ref name=Farag2020/>